MX2022006490A - Uso de inhibidores de sglt-2 en el secado de mamiferos no humanos. - Google Patents

Uso de inhibidores de sglt-2 en el secado de mamiferos no humanos.

Info

Publication number
MX2022006490A
MX2022006490A MX2022006490A MX2022006490A MX2022006490A MX 2022006490 A MX2022006490 A MX 2022006490A MX 2022006490 A MX2022006490 A MX 2022006490A MX 2022006490 A MX2022006490 A MX 2022006490A MX 2022006490 A MX2022006490 A MX 2022006490A
Authority
MX
Mexico
Prior art keywords
sglt
drying
inhibitors
human mammals
human mammal
Prior art date
Application number
MX2022006490A
Other languages
English (en)
Inventor
Dania Birte Reiche
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of MX2022006490A publication Critical patent/MX2022006490A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/20—Inorganic substances, e.g. oligoelements
    • A23K20/24—Compounds of alkaline earth metals, e.g. magnesium
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se refiere al uso de al menos un inhibidor de SGLT-2 en un mamífero no humano, preferentemente rumiante, preferentemente para el secado de un mamífero no humano, preferentemente rumiante, así como métodos correspondientes, tales como mejorar y/o facilitar el secado de un mamífero no humano, preferentemente rumiante, que comprende administrar a tal mamífero no humano, preferentemente rumiante, al menos un inhibidor de SGLT-2.
MX2022006490A 2019-11-28 2020-11-25 Uso de inhibidores de sglt-2 en el secado de mamiferos no humanos. MX2022006490A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19212134 2019-11-28
EP20200103 2020-10-05
PCT/EP2020/083267 WO2021105152A1 (en) 2019-11-28 2020-11-25 Use of sglt-2 inhibitors in the drying-off of non-human mammals

Publications (1)

Publication Number Publication Date
MX2022006490A true MX2022006490A (es) 2022-07-04

Family

ID=73543293

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006490A MX2022006490A (es) 2019-11-28 2020-11-25 Uso de inhibidores de sglt-2 en el secado de mamiferos no humanos.

Country Status (12)

Country Link
US (2) US11759474B2 (es)
EP (1) EP4064854A1 (es)
JP (1) JP7441946B2 (es)
KR (1) KR20220109431A (es)
CN (1) CN114727624A (es)
AU (1) AU2020394498A1 (es)
BR (1) BR112022010385A2 (es)
CA (1) CA3158368A1 (es)
CL (1) CL2022001368A1 (es)
MX (1) MX2022006490A (es)
UY (1) UY38969A (es)
WO (1) WO2021105152A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020012468A (es) 2018-05-23 2021-02-09 Boehringer Ingelheim Vetmedica Gmbh Uso de un bolo oral en el secado de ganado lechero.
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
WO2023227492A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4412993A (en) 1980-01-25 1983-11-01 The Upjohn Company Method of treating pseudopregnancy, galactorrhea and mastitis in mammals
NZ517439A (en) 1999-08-31 2003-03-28 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6391849B1 (en) 1999-11-19 2002-05-21 Agricultural Research Organization, The Volcani Center Method and pharmaceutical composition for disrupting lactation in a mammary gland and for treating and preventing mastitis
WO2002044192A1 (fr) 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions
NZ526715A (en) 2000-12-28 2005-02-25 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives and use thereof in medicines
PL210710B1 (pl) 2002-03-22 2012-02-29 Kissei Pharmaceutical Krystaliczne postaci 2-(4-metoksybenzylo) fenylo-6-O-etoksykarbonylo-ß-D-glukopiranozydu, ich zastosowanie oraz zawierająca je kompozycja farmaceutyczna
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
WO2004080990A1 (ja) 2003-03-14 2004-09-23 Astellas Pharma Inc. Ｃ－グリコシド誘導体又はその塩
US20040258778A1 (en) 2003-03-31 2004-12-23 Farmar Jill B. Lactation cessation and breast engorgement compositions and method of use
GB0313892D0 (en) 2003-06-16 2003-07-23 Hannah Res Inst Control of lactation
PT2896397T (pt) 2003-08-01 2017-11-23 Mitsubishi Tanabe Pharma Corp Novos compostos que possuem actividade inibidora dirigida contra transportadores de glucose dependentes do sódio
US20050191653A1 (en) * 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
EP2295422A3 (de) 2004-03-16 2012-01-04 Boehringer Ingelheim International GmbH Glucopyranosylsubstituierte Benzolderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
JP2008524162A (ja) 2004-12-16 2008-07-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンゼン誘導体、該化合物を含む薬物、その使用及びその製造方法
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
CA2620566A1 (en) 2005-08-30 2007-03-08 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
RU2008113050A (ru) 2005-09-08 2009-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-ЭТИНИЛБЕНЗИН)-БЕНЗОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
US7745414B2 (en) 2006-02-15 2010-06-29 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP2019679B1 (en) 2006-05-23 2018-06-20 Theracos, Inc. Glucose transport inhibitors and methods of use
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TWI403516B (zh) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
US8283326B2 (en) 2006-10-27 2012-10-09 Boehringer Ingelheim International Gmbh Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
JP2010508371A (ja) 2006-11-06 2010-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換フェニル誘導体、該化合物を含有する医薬品及びその使用と製造方法
BRPI0718596B8 (pt) 2006-11-09 2021-05-25 Boehringer Ingelheim Int composições farmacêuticas para terapia de combinação com inibidores de sglt-2 e metformina
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
TW200904454A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
ATE530558T1 (de) 2007-07-26 2011-11-15 Lexicon Pharmaceuticals Inc Verfahren und verbindungen zur herstellung von natriumglucose-co-transporter-2-hemmern
PE20090597A1 (es) 2007-08-16 2009-06-06 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido
FR2920045B1 (fr) 2007-08-16 2010-03-12 Valeo Systemes Thermiques Evaporateur a nappes multiples, en particulier pour un circuit de climatisation de vehicule automobile
BRPI0816258B8 (pt) 2007-09-10 2022-12-27 Mitsubishi Tanabe Pharma Corp processo para a preparação de compostos úteis como inibidores de sglt
BRPI0913129A2 (pt) 2008-05-22 2016-01-05 Bristol Myers Squibb Co método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
BRPI0918841B8 (pt) 2008-08-28 2021-05-25 Pfizer derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos
FR2936710B1 (fr) * 2008-10-07 2011-01-07 Ceva Sante Animale Composition veterinaire antiprolactinique destinee aux ruminants
US8133916B1 (en) 2009-03-10 2012-03-13 Amelgo, LLC Control of milk production and mammary involution
WO2011039107A1 (en) 2009-09-30 2011-04-07 Boehringer Ingelheim International Gmbh Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
IN2012DN02751A (es) 2009-09-30 2015-09-18 Boehringer Ingelheim Int
FR2971423B1 (fr) * 2011-02-15 2014-01-10 Ceva Sante Animale Composition veterinaire antiprolactinique destinee aux ruminants
EP2828281B1 (en) 2012-03-19 2019-09-18 Mileutis Ltd. Peptides for management of lactation
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
ES2900843T3 (es) * 2014-05-16 2022-03-18 Astrazeneca Ab Método para suprimir la secreción de glucagón de un inhibidor de sglt2
JP6027710B1 (ja) * 2014-12-25 2016-11-16 田辺三菱製薬株式会社 糖尿病治療用固形製剤
WO2016134486A1 (en) * 2015-02-27 2016-09-01 Steinberg Gregory Use of canagliflozin and derivatives thereof in the treatment of cancer
EP3341024A1 (en) 2015-08-27 2018-07-04 Boehringer Ingelheim Vetmedica GmbH Liquid pharmaceutical compositions comprising sglt-2 inhibitors
RU2018135961A (ru) 2016-03-18 2020-04-20 Министерство Сельского Хозяйства И Сельскохозяйственной Продукции Ее Величества Королевы Канады По Праву Способ ускорения инволюции и предотвращения инфекции молочной железы дойного животного при запуске
CN111683667A (zh) * 2017-09-12 2020-09-18 加尔文医学研究所 用于减少或关停非人哺乳动物中的泌乳的方法及其试剂
EP3668846A1 (en) 2017-12-19 2020-06-24 Boehringer Ingelheim Vetmedica GmbH Synthesis of the 1 :1 :1 co-crystal of 1 -cyano-2-(4-cyclopropyl-benzyl)-4-(beta-d-glucopyranos-1 -yl)-benzene, l-proline and water

Also Published As

Publication number Publication date
AU2020394498A1 (en) 2022-06-09
CN114727624A (zh) 2022-07-08
WO2021105152A1 (en) 2021-06-03
EP4064854A1 (en) 2022-10-05
UY38969A (es) 2021-05-31
CL2022001368A1 (es) 2023-02-24
CA3158368A1 (en) 2021-06-03
KR20220109431A (ko) 2022-08-04
US20210161930A1 (en) 2021-06-03
BR112022010385A2 (pt) 2022-08-23
JP2023503437A (ja) 2023-01-30
JP7441946B2 (ja) 2024-03-01
US20230338406A1 (en) 2023-10-26
US11759474B2 (en) 2023-09-19

Similar Documents

Publication Publication Date Title
MX2022006490A (es) Uso de inhibidores de sglt-2 en el secado de mamiferos no humanos.
MX2022000711A (es) Inhibidores de parp1.
MX2022007527A (es) Inhibidores de proteinas kras mutantes.
PH12021550052A1 (en) Methods of treating and preventing graft versus host disease
MY185614A (en) Use of myostatin inhibitors and combination therapies
PH12019501010A1 (en) Arginase inhibitor combination therapies
PH12016501668A1 (en) Compositions and methods for the reduction or prevention of hepatic steatosis
MX2020006115A (es) Inhibidores de la vía de respuesta al estrés integrada.
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
NZ729678A (en) Methods of treating non-alcoholic steatohepatitis using ask1 inhibitor in combination with a fxr agonist
MX2021015210A (es) Inhibidores de la via de respuesta al estres integrada.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
NO20082907L (no) Fremgangsmate for anvendelse av IL6 antagonister med proteasom-inhibitorer
MX2020013269A (es) Inhibidores de la vía de respuesta al estrés integrada.
MY197488A (en) Solid compositions for oral administration
MX2018008732A (es) Inhibicion de la reaccion alergica usando un inhibidor de il-33.
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
MX2011009852A (es) Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv.
PH12017501980A1 (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
AR119934A1 (es) Inhibidores de pikfyve para terapia contra el cáncer
WO2015026935A3 (en) Hdac8 inhibitors for treating cancer
MX2021006347A (es) Metodos de tratamiento de cánceres que sobreexpresan whsc1 mediante la inhibición de setd2.
EA202191631A1 (ru) Композиции, содержащие бактериальные штаммы
WO2019204332A3 (en) Pak4 inhibitors and methods of use
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.